Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Phase 3 Recruiting 478 enrolled Shanghai Chest Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.

Timeline

Start: 2024-09-12
Primary completion: 2027-06
Completion: 2029-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Toripalimab	Monoclonal antibody	240 mg	Intravenous
Background	Cisplatin	Other / unclassified	75 mg/m2	Intravenous
Background	Corboplatin	Unknown	5 unknown	Intravenous
Background	Docetaxel	Small molecule	60 mg/m2	Intravenous
Background	Docetaxel	Small molecule	75 mg/m2	Intravenous
Background	Paclitaxel	Small molecule	175 mg/m2	Intravenous
Background	Pemetrexed	Small molecule	500 mg/m2	Intravenous

Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Summary

Timeline

Drugs

Indications